Table 1 Demographics and clinical information of study participants, stratified by vaccine type
| Â | Overall* (n = 33) | J&J (n = 17) | mRNA (n = 16) | p |
|---|---|---|---|---|
Age (years) | 49.8 ± 15.6 | 52.3 ± 13.3 | 47.3 ± 17.7 | 0.066 |
Gender | ||||
 Female | 17/33 (51%) | 8/17 (47%) | 9/16 (56%) | 0.279 |
 Male | 16/33 (49%) | 9/17 (53%) | 7/16 (44%) | |
BMI (kg/m2) | 26.7 ± 5.3 | 27.4 ± 5.2 | 25.9 ± 5.4 | 0.413 |
Race/ethnicity | ||||
 Asian | 10/33 (30%) | 4/17 (24%) | 6/16 (38%) | 0.350 |
 Others | 1/33 (3%) | 0/17 (0%) | 1/16 (6%) | |
 White | 22/33 (67%) | 13/17 (76%) | 9/16 (56%) | |
Hispanic or Latinx | 0/33 (0%) | 0/17 (0%) | 0/16 (0%) | – |
Comorbidities | ||||
 Yes | 10/33 (30%) | 5**/17 (29%) | 5**/16 (31%) | 0.909 |
 No | 23/33 (70%) | 12/17 (71%) | 11/16 (69%) | |
Immunodeficiencies | ||||
 Yes | 3/33 (9%) | 0/17 (0%) | 3***/16 (19%) | 0.061 |
 No | 30/33 (91%) | 17/17 (100%) | 13/16 (81%) | |
Days since vaccination | 168.2 ± 57.9 | 189.7 ± 62.8 | 145.2 ± 43.3 | 0.025 |